RU2003126447A - Вакцины на основе субъединиц с супермотивами а2 - Google Patents

Вакцины на основе субъединиц с супермотивами а2 Download PDF

Info

Publication number
RU2003126447A
RU2003126447A RU2003126447/15A RU2003126447A RU2003126447A RU 2003126447 A RU2003126447 A RU 2003126447A RU 2003126447/15 A RU2003126447/15 A RU 2003126447/15A RU 2003126447 A RU2003126447 A RU 2003126447A RU 2003126447 A RU2003126447 A RU 2003126447A
Authority
RU
Russia
Prior art keywords
epitope
subsequence
indicated
hla
peptide
Prior art date
Application number
RU2003126447/15A
Other languages
English (en)
Russian (ru)
Inventor
Джон СИДНИ (US)
Джон СИДНИ
Алессандро СЕТТЕ (US)
Алессандро СЕТТЕ
Говард М. ГРЭЙ (US)
Говард М. ГРЭЙ
Скотт САУТВУД (US)
Скотт САУТВУД
Original Assignee
Эпиммьюн Инк. (Us)
Эпиммьюн Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпиммьюн Инк. (Us), Эпиммьюн Инк. filed Critical Эпиммьюн Инк. (Us)
Publication of RU2003126447A publication Critical patent/RU2003126447A/ru

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806Determination of free amino acids
    • G01N33/6812Assays for specific amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2003126447/15A 2001-01-29 2002-01-29 Вакцины на основе субъединиц с супермотивами а2 RU2003126447A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26496901P 2001-01-29 2001-01-29
US60/264,969 2001-01-29
US09/935,476 2001-08-22
US09/935,476 US20040096445A1 (en) 1999-06-30 2001-08-22 Subunit vaccines with A2 supermotifs

Publications (1)

Publication Number Publication Date
RU2003126447A true RU2003126447A (ru) 2005-02-27

Family

ID=26950859

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003126447/15A RU2003126447A (ru) 2001-01-29 2002-01-29 Вакцины на основе субъединиц с супермотивами а2

Country Status (14)

Country Link
US (1) US20040096445A1 (https=)
EP (1) EP1368659A2 (https=)
JP (1) JP2005512016A (https=)
KR (1) KR20040052475A (https=)
CN (1) CN1653337A (https=)
AU (1) AU2002243730B2 (https=)
CA (1) CA2432995C (https=)
CZ (1) CZ20032054A3 (https=)
IL (1) IL156660A0 (https=)
MX (1) MXPA03006581A (https=)
NZ (1) NZ526860A (https=)
RU (1) RU2003126447A (https=)
SK (1) SK9512003A3 (https=)
WO (1) WO2002061435A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
CA2685270C (en) * 1998-05-13 2014-07-29 Pharmexa Inc. Expression vectors for stimulating an immune response and methods of using the same
EP1200109A4 (en) * 1999-07-19 2005-06-15 Epimmune Inc USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
US20070054262A1 (en) * 2003-03-28 2007-03-08 Baker Denise M Methods of identifying optimal variants of peptide epitopes
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
CA3045811A1 (en) * 2016-12-01 2018-06-07 Nantomics, Llc Tumor antigenicity processing and presentation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000225A1 (en) * 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
CA2394741A1 (en) * 1999-12-21 2001-06-28 Epimmune Inc. Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions

Also Published As

Publication number Publication date
EP1368659A2 (en) 2003-12-10
CZ20032054A3 (cs) 2003-12-17
CN1653337A (zh) 2005-08-10
JP2005512016A (ja) 2005-04-28
CA2432995C (en) 2011-07-26
AU2002243730B2 (en) 2007-07-12
WO2002061435A2 (en) 2002-08-08
WO2002061435A3 (en) 2003-07-10
CA2432995A1 (en) 2002-08-08
US20040096445A1 (en) 2004-05-20
SK9512003A3 (en) 2003-12-02
MXPA03006581A (es) 2004-06-25
NZ526860A (en) 2007-03-30
KR20040052475A (ko) 2004-06-23
IL156660A0 (en) 2004-01-04

Similar Documents

Publication Publication Date Title
RU2003126447A (ru) Вакцины на основе субъединиц с супермотивами а2
ATE468127T1 (de) Ii-key/antigene epitop-hybrid-peptid-vakzine
WO2006076410A3 (en) Li-key/antigenic epitope hybrid peptide vaccines
JP2004512814A5 (https=)
DK0721346T3 (da) Fremgangsmåde til induktion af antigenspecifik T-celletolerance
EP1630229A3 (en) Melanoma antigens
ATE401390T1 (de) Zytokin (zcytor17-ligand)
Hammer New methods to predict MHC-binding sequences within protein antigens
NO20081043L (no) Vaksine for fisk
ATE387629T1 (de) Gemeinsame epitope von antigenen aus einer multigen-familie
IL273648B2 (en) Microbiota sequence variants of tumor-related antigenic epitopes
WO2002080649A3 (en) Methods and systems for searching genomic databases
WO2002072614A3 (en) Algorithmic design of peptides for binding and/or modulation of the functions of receptors and/or other proteins
WO2004030616A3 (en) Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
JP2005512016A5 (https=)
EA200600738A1 (ru) Способ
Sledge et al. Antibody structure: amino terminal sequences of nurse shark light and heavy chains
Muller Molecular dissection of protein antigens and the prediction of epitopes
RU2005108044A (ru) Эпитопы т-клеток в стафилококковом энтеротоксине в
Krikorian et al. A peptide carrier with a built-in vaccine adjuvant: construction of immunogenic conjugates
CA2542104A1 (en) Method for the identification of epitopes related to immunogenicity in biopharmaceuticals
Sadler et al. Synthetic peptide epitope‐based polymers: controlling size and determining the efficiency of epitope incorporation
Phan-Chan-Du et al. Structure of Antibody-Bound Peptides and Retro− Inverso Analogues. A Transferred Nuclear Overhauser Effect Spectroscopy and Molecular Dynamics Approach
JP2004509858A5 (https=)
McLean et al. Rapid attachment of a helper T cell epitope to branched peptides by fragment condensation to give enhanced immunogenicity

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20060818